IL33/ST2 was first implicated in CRC in early studies that showed increased IL-33 expression in CRC patient tissues as compared to non-cancer adjacent tissues, correlating with transition from adenoma to carcinoma progression [64]. This evidence concerns the gene IL33 and cancer.